Antibodies to HBV surface antigen in relation to interferon-λ3 in hemodialysis patients

被引:9
|
作者
Grzegorzewska, Alicja E. [1 ]
Swiderska, Monika K. [2 ,3 ]
Mostowska, Adrianna [4 ]
Warchol, Wojciech [5 ]
Jagodzinski, Pawel P. [4 ]
机构
[1] Poznan Univ Med Sci, Chair & Dept Nephrol Transplantol & Internal Dis, Przybyszewskiego 49,49 Przybyszewskiego Blv, PL-60355 Poznan, Poland
[2] Poznan Univ Med Sci, Student Nephrol Res Grp, Przybyszewskiego 49, PL-60355 Poznan, Poland
[3] Poznan Univ Med Sci, Chair & Dept Nephrol Transplantol & Internal Dis, Przybyszewskiego 49, PL-60355 Poznan, Poland
[4] Poznan Univ Med Sci, Chair & Dept Biochem & Mol Biol, Swiecickiego 6, PL-60781 Poznan, Poland
[5] Poznan Univ Med Sci, Chair & Dept Biophys, Grunwaldzka 6, PL-60780 Poznan, Poland
关键词
Anti-HBs; Hemodialysis; IFNL3; Infection; Interferon-X3; Vaccination; HEPATITIS-B-VIRUS; SINGLE NUCLEOTIDE POLYMORPHISMS; GENOME-WIDE ASSOCIATION; GENE POLYMORPHISMS; INTERLEUKIN; 28B; RIBAVIRIN THERAPY; IL28B RS12979860; BINDING-PROTEIN; VACCINATION; IMMUNIZATION;
D O I
10.1016/j.vaccine.2016.08.073
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aim: To investigate circulating IFN-73 and IFNL3 polymorphisms in hemodialysis (HD) patients differing in HBV surface antigen antibody (anti-HBs) production. Methods: The study included 106 HBV-vaccinated HD patients (88 developed anti-HBs) and 36 HBV-infected HD subjects (27 developed anti-HBs). Plasma IFN-lambda 3 (enzyme-linked immunosorbent assay) and rs12979860 (C > T) and rs8099917 (T > G) in IFNL3 (high-resolution melting curve analysis) were analyzed with regard to the association with anti-HBs production in response to HBV vaccination or infection. The results were adjusted for gender, age, cause of renal disease, dialysis vintage, dialysis modality, IFN-lambda 3, and 25(OH)D as appropriate. Results: HBV vaccine responders had higher circulating IFN-lambda 3 (ng/L) than non-responders (120, 36-233 vs. 53, 33-109, P < 0.000001). Patients who generated anti-HBs after HBV infection also had higher circulating IFN-lambda 3 levels than those who did not (133, 35-215 vs. 71, 9-229, P = 0.043). The IFN-lambda 3 concentration correlated with the anti-HBs titer in vaccinated (r = 0.614, P < 0.000001) and infected patients (r = 0.589, P = 0.0002). Plasma IFN-lambda 3 was the only significant indicator of responsiveness to HBV vaccination (adjusted P = 0.018) and remained the only significant associate for the development of post infection anti-HBs (adjusted P = 0.049). A plasma IFN-lambda 3 level of 85.5 ng/L was the cut-off value for the prognosis of an anti-HBs titer below vs. equal to or over 101U/L in the entire group of HD patients (ROC sensitivity 68.7%, specificity 85.2%, and AUC 0.827). Significant associations were not found between IFN-lambda 3 and IFNL3 rs12979860. Subjects treated with low flux HD that harbored the TT genotype in rs8099917 showed higher IFN-lambda 3 levels than patients bearing the G allele in rs8099917 (139, 68-233 vs. 103, 9-208, P = 0.049). Conclusion: In HD patients, circulating IFN-lambda 3 strongly correlates with anti-HBs production after HBV vaccination and infection. IFNL3 rs8099917 polymorphisms seem to be associated with IFN-lambda 3 plasma levels in HD subjects. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4866 / 4874
页数:9
相关论文
共 50 条
  • [31] Dynamics of interferon-β modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-β neutralizing antibodies
    Santos, Roseane
    Weinstock-Guttman, Bianca
    Tamano-Blanco, Miriam
    Badgett, Darlene
    Zivadinov, Robert
    Justinger, Theresa
    Munschauer, Frederick, III
    Ramanathan, Murali
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 176 (1-2) : 125 - 133
  • [33] Interleukin-18 Promoter Polymorphism and Development of Antibodies to Surface Antigen of Hepatitis B Virus in Hemodialysis Patients
    Grzegorzewska, Alicja E.
    Wobszal, Piotr
    Jagodzinski, Pawel P.
    KIDNEY & BLOOD PRESSURE RESEARCH, 2012, 35 (01): : 1 - 8
  • [34] Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients
    Alicja E Grzegorzewska
    Piotr M Wobszal
    Adrianna Mostowska
    Paweł P Jagodziński
    BMC Nephrology, 13
  • [35] Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients
    Grzegorzewska, Alicja E.
    Wobszal, Piotr M.
    Mostowska, Adrianna
    Jagodzinski, Pawel P.
    BMC NEPHROLOGY, 2012, 13
  • [36] Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a
    Moucari, Rami
    Martinot-Peignoux, Michelle
    Mackiewicz, Vincent
    Boyer, Nathalie
    Ripault, Marie-Pierre
    Castelnau, Corinne
    Leclere, Laurence
    Dauvergne, Agnes
    Valla, Dominique
    Vidaud, Michel
    Nicolas-Chanoine, Marie-Helene
    Marcellin, Patrick
    ANTIVIRAL THERAPY, 2009, 14 (08) : 1183 - 1188
  • [37] Suppression of hepatocellular carcinoma proliferation and hepatitis B surface antigen secretion with interferon-λ1 or PEG-interferon-λ1
    Tian, Shuo
    Hui, Xiwu
    Fan, Zhenzhen
    Li, Qinshan
    Zhang, Junwen
    Yang, Xia
    Ma, Xiaoli
    Huang, Bingren
    Chen, Deng
    Chen, Hong
    FASEB JOURNAL, 2014, 28 (08): : 3528 - 3539
  • [38] Analysis of surface promoter mutants of HBV: its relation to hepatitis B surface antigen production and secretion
    Sengupta, S.
    Durgapal, H.
    Panda, S. K.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S68 - S68
  • [39] Anemia associated with pegylated interferon-α2a and α2b therapy in hemodialysis patients
    Espinosa, M.
    Arenas, M. D.
    Aumente, M. D.
    Barril, G.
    Buades, J. M.
    Aviles, B.
    Carretero, D.
    Alvarez-Lara, M. A.
    Carnicer, F.
    Martin-Malo, A.
    Ajama, P.
    CLINICAL NEPHROLOGY, 2007, 67 (06) : 366 - 373
  • [40] A weighted genetic risk score to predict neutralising antibodies to interferon-β in multiple sclerosis patients
    Hemmer, B.
    Igl, W.
    Buck, D.
    Muehlau, M.
    Schwenke, S.
    Mueller-Myhsok, B.
    Sandbrink, R.
    Pohl, C.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 361 - 361